SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001867096-22-000107
Filing Date
2022-08-10
Accepted
2022-08-10 16:16:59
Documents
82
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q xers-20220630.htm   iXBRL 10-Q 1855475
2 EX-10.1 bachemxpi-secondamendment.htm EX-10.1 32533
3 EX-31.1 q22022exhibit311.htm EX-31.1 10929
4 EX-31.2 q22022exhibit312.htm EX-31.2 10784
5 EX-32.1 q22022exhibit321.htm EX-32.1 7453
  Complete submission text file 0001867096-22-000107.txt   8469960

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20220630.xsd EX-101.SCH 59935
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20220630_cal.xml EX-101.CAL 67169
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20220630_def.xml EX-101.DEF 323720
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20220630_lab.xml EX-101.LAB 760056
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20220630_pre.xml EX-101.PRE 484796
76 EXTRACTED XBRL INSTANCE DOCUMENT xers-20220630_htm.xml XML 1294284
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40880 | Film No.: 221152060
SIC: 2834 Pharmaceutical Preparations